SG11202004939SA - Methods for using cd137 ligand as a biomarker for treatment with anti-cd137 antibody - Google Patents

Methods for using cd137 ligand as a biomarker for treatment with anti-cd137 antibody

Info

Publication number
SG11202004939SA
SG11202004939SA SG11202004939SA SG11202004939SA SG11202004939SA SG 11202004939S A SG11202004939S A SG 11202004939SA SG 11202004939S A SG11202004939S A SG 11202004939SA SG 11202004939S A SG11202004939S A SG 11202004939SA SG 11202004939S A SG11202004939S A SG 11202004939SA
Authority
SG
Singapore
Prior art keywords
biomarker
ligand
antibody
treatment
methods
Prior art date
Application number
SG11202004939SA
Other languages
English (en)
Inventor
Peter Peizhi Luo
Guizhong Liu
Fangyong Du
Original Assignee
Adagene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adagene Inc filed Critical Adagene Inc
Publication of SG11202004939SA publication Critical patent/SG11202004939SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202004939SA 2017-12-01 2018-11-30 Methods for using cd137 ligand as a biomarker for treatment with anti-cd137 antibody SG11202004939SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2017/114247 WO2019104716A1 (en) 2017-12-01 2017-12-01 Methods for using cd137 ligand as biomarker for treatment with anti-cd137 antibody
PCT/CN2018/118631 WO2019105468A1 (en) 2017-12-01 2018-11-30 Methods for using cd137 ligand as a biomarker for treatment with anti-cd137 antibody

Publications (1)

Publication Number Publication Date
SG11202004939SA true SG11202004939SA (en) 2020-06-29

Family

ID=66664325

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202004939SA SG11202004939SA (en) 2017-12-01 2018-11-30 Methods for using cd137 ligand as a biomarker for treatment with anti-cd137 antibody

Country Status (8)

Country Link
US (1) US20200377608A1 (https=)
EP (1) EP3717010A4 (https=)
JP (1) JP2021507877A (https=)
CN (1) CN111344014A (https=)
AU (1) AU2018377751A1 (https=)
CA (1) CA3079479A1 (https=)
SG (1) SG11202004939SA (https=)
WO (2) WO2019104716A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018224094B2 (en) 2017-02-24 2025-04-17 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. Anti-cd137 molecules and use thereof
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
TWI841551B (zh) * 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
SG11202007961QA (en) * 2018-04-13 2020-09-29 Hoffmann La Roche Her2-targeting antigen binding molecules comprising 4-1bbl
CN112739339B (zh) 2018-07-23 2024-12-27 海德堡医药研究有限责任公司 抗cd137抗体药物缀合物(adc)在同种异体细胞疗法中的用途
KR20220087479A (ko) * 2019-11-13 2022-06-24 허페이 한커맵 바이오테크놀로지 컴퍼니 리미티드 인간 4-1bb와 결합할 수 있는 분자 및 이의 응용
WO2021226883A1 (en) * 2020-05-13 2021-11-18 Adagene Ag Compositions and methods for treating cancer submission of sequence listing on ascii text file
EP4559477A3 (en) 2020-05-13 2025-08-13 Adagene AG Compositions and methods for treating cancer
EP4168048A4 (en) * 2020-06-23 2024-10-16 Adagene Pte. Ltd. COMBINATION THERAPY INCLUDING ANTI-CD137 ANTIBODIES
GB202210957D0 (en) * 2022-07-27 2022-09-07 Alligator Bioscience Ab Novel dosages
GB202210965D0 (en) * 2022-07-27 2022-09-07 Alligator Bioscience Ab Novel dosages

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030118588A1 (en) * 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
US20070253961A1 (en) * 2004-06-09 2007-11-01 Ulsan Industrial Education Foundation Pharmaceutical Composition Comprising the Anti-4-1Bb Antibody for Treating or Preventing Rheumatoid Arthritis
DK2439273T3 (da) * 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
CN1294146C (zh) * 2005-10-17 2007-01-10 山东大学 与t细胞表面共刺激分子cd137结合的多肽及其应用
ES2336873B1 (es) * 2007-11-07 2011-01-24 Proyecto De Biomedicina Cima, S.L. Composicion farmaceutica para el tratamiento de cancer.
SG11201604965RA (en) * 2013-12-20 2016-07-28 Univ Singapore Differentiation therapy with cd137 ligand agonists
KR20180016972A (ko) * 2015-02-22 2018-02-20 소렌토 쎄라퓨틱스, 인코포레이티드 Cd137에 결합하는 항체 치료제
JP6845846B6 (ja) * 2015-09-22 2021-04-21 ディンフー バイオターゲット カンパニー リミテッド 抗ヒトｃｄ１３７の完全ヒト抗体及びその用途
ES2986067T3 (es) * 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas

Also Published As

Publication number Publication date
CA3079479A1 (en) 2019-06-06
JP2021507877A (ja) 2021-02-25
CN111344014A (zh) 2020-06-26
WO2019105468A8 (en) 2020-05-14
AU2018377751A1 (en) 2020-07-16
EP3717010A1 (en) 2020-10-07
US20200377608A1 (en) 2020-12-03
WO2019104716A1 (en) 2019-06-06
WO2019105468A1 (en) 2019-06-06
EP3717010A4 (en) 2021-09-01

Similar Documents

Publication Publication Date Title
SG11202004939SA (en) Methods for using cd137 ligand as a biomarker for treatment with anti-cd137 antibody
IL288649A (en) Human antibodies against tau
SG11202000747VA (en) Anti-cd137 antibodies
SG11201605580RA (en) Antibodies directed against interleukin-33 (il-33)
PT3285784T (pt) Método para preparar uma amostra de microbiota fecal
SG11201607030PA (en) Antibodies, uses & methods
IL252716A0 (en) Anti-csf1r antibodies for the treatment of pvns
ZA201700824B (en) Carrier molecule for antigens
IL247277A0 (en) Monoclonal antibodies against Ebola
PT3166970T (pt) Anticorpos de ligação a protofibrilas a-beta aperfeiçoados
IL266564A (en) Methods for treating obesity with anti-angptl8 antibodies
PL3178803T3 (pl) Sposób wytwarzania 2,3,3,3-tetrafluoropropenu
SG11201701875YA (en) Methods for detecting ovarian cancer
ZA201608777B (en) Method for preparing methyl mercaptan
GB201905146D0 (en) Method for preparing aronatic hydrocarbons
HUE054626T2 (hu) Eljárás D-arginil-2,6-dimetil-L-tirozil-L-lizil-L-fenilalaninamid elõállítására
PL3224225T3 (pl) Sposób wytwarzania etenu
PL3508512T3 (pl) Sposób wytwarzania poliwęglanu
PL3224226T3 (pl) Sposób wytwarzania etenu
HK40037607A (en) Methods for using cd137 ligand as a biomarker for treatment with anti-cd137 antibody
GB2527129B (en) Method for preparing a ninhydrin reagent
GB201413950D0 (en) Antibodies, uses & methods
GB201400597D0 (en) Antibodies, uses & methods
GB201409660D0 (en) Method for preparing a sorbent